The US Build-Up for War with China
– Visit by US Secretary of State attempts to portray the US as “reasonable” versus a “belligerent” Chinese “dictatorship;”
– Secretary Blinken recited the US “One China” policy, omitting the many ways the US has and still is blatantly violating it and provoking China;
– US strategy follows similar pattern of the US “reset” with Russia or the US-Iran “nuclear deal,” where the US sought to appear to have exhausted diplomatic options before moving on “reluctantly” to economic sanctions and war;
– Such a strategy is necessary for consensus building among US allies who would otherwise be hesitant to join the US in both economic sanctions and eventual military intervention versus China;
– US policymakers are already busy planning sanctions against China, which includes an already ongoing public relations campaign to sell Russia-style sanctions against China, as well as preparations for military operations to follow the sanctions;
– The US has a long-standing strategy to encircle and contain China spanning decades, indifferent to presidential administrations;
References:
Washington’s REAL Policy on China – “Repairing Ties” is Theater Ahead of Sanctions, War (Rumble) via The New Atlas
Tag: Merck & Co
Beijing to Let Some Low-Risk Patients Home Quarantine as Covid Soars + Some Notes
Bloomberg: Beijing to Let Some Low-Risk Patients Home Quarantine as Covid Soars
Global Times: Flexible measures implemented across China to ensure people’s livelihoods amid cold front
China actually started relaxing it’s Zero-COVID polices on November 11th. The mNRA vaccine hasn’t been approved, yet. The West is pushing for China to use mNRA vaccines.
Related:
05-09-2022: Dropping zero-COVID policy in China without safeguards risks 1.5m lives – study
China’s refusal to use Western COVID-19 vaccines is making its protest problems even worse
Read More »Pfizer’s anti-COVID pill Paxlovid shows no benefit for younger adults
Pfizer’s anti-COVID pill Paxlovid shows no benefit for younger adults
The report’s authors found that Pfizer’s antiviral medication Paxlovid offered little to no benefit for younger adults. However, it did reduce the risk of hospitalization for high-risk seniors. Notably, supplementary material from the original study of Paxlovid in high-risk non-hospitalized adults with COVID-19 during the Delta wave had demonstrated benefits in those younger than 65, albeit the difference compared to the placebo was much less than in those 65 and older.
…
Among those over 65, there was a 73 percent decrease in the hospitalization rate and a 79 percent reduction in the risk of death. However, patients between the ages of 40 and 65 saw no benefit in taking the antiviral medication in either category, regardless of previous immunity status.
…
Another critical study from Hong Kong published in Lancet Infectious Diseases on the same day as the Israeli study but which went unmentioned in the press offered further evidence of Paxlovid’s limited therapeutic role. The authors reviewed their clinical experience with Paxlovid and Lagevrio, Merck’s antiviral pill, Molnupiravir, in hospitalized patients. They compared them to hospitalized patients who did not receive those medications during the horrific wave of infections that slammed into the semi-autonomous region in February and March.
…
The mortality risk reduction for Lagevrio was 52 percent, and for Paxlovid it was 66 percent. Those receiving antivirals had a lower risk of their disease progressing, but the drugs did not significantly impact their need for mechanical ventilation or ICU admission. The patients in the study averaged in age from mid-70s to early 80s.
…
Given the results of these studies, it bears mentioning that the Centers for Disease Control and Prevention (CDC) has recently estimated that approximately 95 percent of Americans aged 16 and older have some level of immunity against COVID-19.
Ms. Cat’s Chronicles 